A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Active:	No
Cancer Type:	Lung Cancer	NCT ID:	NCT04620330
Trial Phases:	Phase II	Protocol IDs:	VS-6766-202 (primary) NCI-2021-01997
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Verastem Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT04620330

Summary

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or
VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.

Objectives

This is a multicenter, open-label Phase 2 study designed to evaluate safety and tolerability
and efficacy of avutometinib (VS-6766) versus avutometinib (VS-6766) in combination with
defactinib in subjects with KRAS and BRAF mutant NSCLC following treatment with an
appropriate platinum-based regimen and an approved immune checkpoint inhibitor (CPI).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.